«Yissum Introduces a Novel Method for Treating Cancer Based on a Protein

Encoded by HIV-1»«DNA repair gene

involved in tumours»

Sara Sofia Buelvas LondoñoMedical Student III SemesterMolecular Biology- Lina Martinez S.August 12th 2012 UPB.

FOR CANCER TREATMENT

new findings by

The Garvan Institute of Medical research

Research and development Company of the Hebrew University of

Jerusalemconsist

Expression levels of DNA repair gene

(MGMT) may play a significant role in

tumour progression and indicates resistance to

chemotherapy

consist

ViF: a isolated protein from HIV-1

can be use to increase the

sensitivity of cancer cells to radiotherapy and chemotherapy

DNA gene repair involved in tumours

MGMT(gene)

a biomarker of response to temozolomide, a chemotherapeutic agent.

may also play a significant role in tumour progression

DNA gene repair involved in tumours

MGMT(gene)

expressed in pituitary tumours.

In different

levels

LOW

HIGH

DNA gene repair involved in tumours

TUMOURS with low levels of MGMT are more agressive but also tend to respond to chemotherapy because the gene can’t no longer undo the damage caused by the drug-

Loss of MGMT expression may contribute to the progressive accumulation of genetic mutations and cellular proliferation that occurs.

DNA gene repair involved in tumours

DNA gene repair involved in tumours

Knowing genes involved in cancer , finding a cure is easier and kwowing the response that some cancers have is veryhelpful to give a determinated kind of treatment.

PERSONAL

OPINION

Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded

by HIV-1

ViF(HIV-1

protein)inhibits DNA repair specifically in activated hematopoietic cells following exposure to ionizing radiation.

rendering them more susceptible to radiotherapy and chemotherapy.

small peptide derived from the HIV-1 Vif protein

Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded

by HIV-1Vif-

derived peptide prevents DNA

repair by inhibiting a protein : A3G

responsible for anti-viral innate immunity and also plays a role in DNA repair in lymphoid and myeloid malignancies.

Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded

by HIV-1The novel Vif peptide has already been shown to significantly increase the efficiency of radiation therapy in cultured lymphoma and myeloma cells beacause the inhibition of the protein don’t let the cells being repair.

Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded

by HIV-1

An elevated DNA break-repair capacity in several cancer cells often leads to radiation resistance and severely limits the efficacy of radiation treatment and chemotherapy, for this reason is important the novel method of repair inhibition.

Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded

by HIV-1

PERSONAL

OPINION

This study is a new oportunity for the management of cancer, it gives another perspective for the treatment and a very big advance in the search of the cancer cure.

MEDICAL

UTILITYCancer is the second leading cause of death in the world. Because of that the knowledge of all the components is really important for the management of the desease.

MEDICAL

UTILITYThe first steps in every investigation stimulates investigator to continue researching and find results usefull to the humanity, so this novel methods can be improved for the human benefit.

MEDICAL

UTILITY

Discover genes that are expressed in different kind of cancer helps to know what treatment is more effective or view if the cells have an adecuate response to the chemotherapy

MEDICAL

UTILITY

The treatment with proteins with no know essential functions involving normal cell physiology may have minimal side effects, a very important fact for the patients .

BIBLIOGRAPHYDNA repair gene involved in tumours(sciencealert, 30 JULY 2012 )

 Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded by HIV-1 (marketwatch, 9 JULY 2012)

 MARTINEZ SÁNCHEZ, Lina María. Biología molecular. 2. ed. Medellín: UPB. Fac. de Medicina, 2006. 208 p.